← All Compounds
Mechanism Activates three receptors simultaneously: GIP (enhances insulin), GLP-1 (suppresses appetite, slows gastric emptying), and glucagon (increases energy expenditure and hepatic fat oxidation). The glucagon component distinguishes it from dual agonists. Half-Life Approximately 6 days (144 hours) Route subcutaneous Frequency Once weekly
FDA Category Investigational (Phase 3) Reclassification stable
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
Retatrutide
InvestigationalTriple Agonist · Eli Lilly
Investigational triple-agonist targeting GIP, GLP-1, and glucagon receptors. In Phase 3 clinical trials (TRIUMPH program) by Eli Lilly for obesity and type 2 diabetes.
About
Clinical Dosing
2-12 mgonce weekly
Not FDA-approved. Available only through clinical trials or research supply. Phase 3 results expected 2025-2026.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Phase 2 Trial Titration (12 mg arm)
Source: Jastreboff et al., NEJM 2023 — Triple-Hormone-Receptor Agonist Retatrutide for Obesity
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 2 mg | 4 weeks | 0.80 mL (80 units) | Starting dose |
| 4 mg | 4 weeks | 1.60 mL (160 units) | First escalation |
| 6 mg | 4 weeks | 2.40 mL (240 units) | Second escalation |
| 8 mg | 4 weeks | 3.20 mL (320 units) | Third escalation |
| 10 mg | 4 weeks | 4.00 mL (400 units) | Fourth escalation |
| 12 mg | Maintenance | 4.80 mL (480 units) | Target dose |
TRIUMPH Phase 3 (12 mg target)
Source: Eli Lilly TRIUMPH-4 results, Dec 2025
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 2 mg | 4 weeks | 0.80 mL (80 units) | Starting dose |
| 4 mg | 4 weeks | 1.60 mL (160 units) | First escalation |
| 6 mg | 4 weeks | 2.40 mL (240 units) | Second escalation |
| 9 mg | 4 weeks | 3.60 mL (360 units) | Third escalation (skips 8mg) |
| 12 mg | Maintenance | 4.80 mL (480 units) | Target dose |
Available Vial Sizes
5 mg
5 mg vial
10 mg
10 mg vial